A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

NHS health staff have been issued an alert over a small increased risk of a rare condition ion people vaccinated against the ...

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...

Residents in public residential aged care services aged 60 and over can now claim a free vaccine for Respiratory Syncytial ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Abrysvo is already approved for use in older adults agreed 60 and above, where it faces competition from GSK's Arexvy, and an FDA decision on maternal use is due in August.